A rating scale for drug-induced akathisia
- PMID: 2574607
- DOI: 10.1192/bjp.154.5.672
A rating scale for drug-induced akathisia
Abstract
A rating scale for drug-induced akathisia has been derived that incorporates diagnostic criteria for pseudoakathisia, and mild, moderate, and severe akathisia. It comprises items for rating the observable, restless movements which characterise the condition, the subjective awareness of restlessness, and any distress associated with the akathisia. In addition, there is an item for rating global severity. A standard examination procedure is recommended. The inter-rater reliability for the scale items (Cohen's kappa) ranged from 0.738 to 0.955. Akathisia was found in eight of 42 schizophrenic in-patients, and nine had pseudoakathisia, where the typical sense of inner restlessness was not reported.
Similar articles
-
Akathisia variants and tardive dyskinesia.Arch Gen Psychiatry. 1985 Sep;42(9):874-8. doi: 10.1001/archpsyc.1985.01790320042006. Arch Gen Psychiatry. 1985. PMID: 2864031
-
Akathisia: clinical phenomenology and relationship to tardive dyskinesia.Compr Psychiatry. 1992 Jul-Aug;33(4):233-6. doi: 10.1016/0010-440x(92)90046-s. Compr Psychiatry. 1992. PMID: 1353716
-
Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia.Br J Psychiatry. 1994 Feb;164(2):177-83. doi: 10.1192/bjp.164.2.177. Br J Psychiatry. 1994. PMID: 7909711
-
Chronic restlessness with antipsychotics.Am J Psychiatry. 2007 Nov;164(11):1648-54. doi: 10.1176/appi.ajp.2007.07071150. Am J Psychiatry. 2007. PMID: 17974927 Review. No abstract available.
-
The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.Psychiatr Dev. 1987 Winter;5(4):301-19. Psychiatr Dev. 1987. PMID: 2895467 Review.
Cited by
-
Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study.J Autism Dev Disord. 2013 Aug;43(8):1773-83. doi: 10.1007/s10803-012-1723-5. J Autism Dev Disord. 2013. PMID: 23212807 Clinical Trial.
-
Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.Eur Arch Psychiatry Clin Neurosci. 2013 Feb;263(1):65-74. doi: 10.1007/s00406-012-0348-1. Epub 2012 Aug 15. Eur Arch Psychiatry Clin Neurosci. 2013. PMID: 22893251 Clinical Trial.
-
Comments on Lucire and Crotty, 2011.Pharmgenomics Pers Med. 2016 Aug 18;9:85-7. doi: 10.2147/PGPM.S111666. eCollection 2016. Pharmgenomics Pers Med. 2016. PMID: 27574461 Free PMC article. No abstract available.
-
D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.Psychopharmacology (Berl). 2012 Dec;224(4):549-57. doi: 10.1007/s00213-012-2782-1. Epub 2012 Jul 7. Psychopharmacology (Berl). 2012. PMID: 22773165 Clinical Trial.
-
Escitalopram-induced akathisia in a patient with major depressive disorder: A rare case report.SAGE Open Med Case Rep. 2022 Nov 28;10:2050313X221139710. doi: 10.1177/2050313X221139710. eCollection 2022. SAGE Open Med Case Rep. 2022. PMID: 36467010 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical